CYP2C19基因多态性对晚期非小细胞肺癌紫杉醇联合顺铂方案的疗效影响

Influence of CYP2C19 gene polymorphisms for the drug efficacy of paclitaxel and cisplatin on ad- vanced non-smaU cell lung cancer

目的探讨CYP2C19基因多态性与非小细胞肺癌紫杉醇联合顺铂方案疗效和不良反应的关系。方法通过基因芯片技术检测患者的CYP2C19的基因型，将患者分成EM组和PM组，比较两组之间疗效和不良反应的差异。结果87例非小细胞肺癌患者中EM组65例（74．7％），PM组22例（25．3％），EM组和PM组的有效率分别为52．3％、50．0％，疾病控制率分别为81．3％、77．3％，两组比较差异无统计学意义（P〉0．05）。EM组恶心、呕吐、肌肉或关节疼痛的发生率低于PM组（P〈0．05）。结论CYP2C19基因多态性影响紫杉醇联合顺铂方案治疗晚期非小细胞肺癌的不良反应，未发现对近期疗效的影响。

Objective To investigate the relationship between CYP2CI9 gene polymorphisms and the drug efficacy and adverse drug reactions of paclitaxel and cisplatin for non-small cell lung cancer （NSCLC）. Methods Gene chip technology was used to detect the polymorphisms of CYP2C19 in non- small cell lung cancer patients. Patients were divided into EM group and PM group according to CYP2C19 genotype. The differences of drug efficacy and adverse reactions between the two groups were compared. Results In the 87 patients with non small cell lung cancer, 65 cases （74.4%）were EMs, 22 cases （25.5%） were PMs. The overall response rates of EM group and PM groups were 52. 3% and 50. 0% , the disease control rates were 81.3 % and 77. 3 % （P 〉 0. 05 ）. The incidence rates of nausea, vomitting, muscle soreness in EM group were lower than those in PM group （P 〈 0. 05 ）. Conclusions The gene polymorphisms of CYP2C19 can not affect the curative effect of paclitaxel and cisplatin on non-small cell lung cancer, but it can affect the adverse drug reactions.